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Abstract 36 
Background: Despite recent advances in treatment strategies, it is still difficult to 37 
cure patients with hepatocellular carcinoma (HCC). Sorafenib is the only approved 38 
multiple kinase inhibitor for systemic chemotherapy in patients with advanced HCC. The 39 
majority of advanced HCC patients are resistant to sorafenib. The mechanisms of 40 
sorafenib resistance are still unknown. 41 
Methods: The expression of molecules involved in the mitogen-activated protein 42 
kinase (MAPK) signaling pathway in human hepatoma cell lines was examined in the 43 
presence or absence of sorafenib. Apoptosis of human hepatoma cells treated with 44 
sorafenib was investigated, and the expression of Jun proto-oncogene (c-Jun) was 45 
measured. 46 
Results: The expression and phosphorylation of c-Jun were enhanced in human 47 
hepatoma cell lines after treatment with sorafenib. Inhibiting c-Jun enhanced sorafenib-48 
induced apoptosis. The overexpression of c-Jun impaired sorafenib-induced apoptosis. 49 
The expression of osteopontin, one of the established AP-1 target genes, was enhanced 50 
after treatment with sorafenib in human hepatoma cell lines. 51 
Conclusions: The protein c-Jun plays a role in sorafenib resistance in human 52 
hepatoma cell lines. The modulation and phosphorylation of c-Jun could be a new 53 
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therapeutic option for enhancing responsiveness to sorafenib. Modulating c-Jun may be 54 
useful for certain HCC patients with sorafenib resistance.  55 
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Introduction 56 
The estimated number of new cases of liver cancer in 2012 was 782,000 worldwide, 57 
including 554,000 and 228,000 cases in men and women, respectively [1]. The 58 
estimated number of cancer deaths from liver cancer in 2012 was 745,000 worldwide, 59 
including 521,000 and 224,000 deaths in men and women, respectively [1]. The very 60 
small difference between the numbers of new cases and deaths from liver cancer 61 
indicates a poor prognosis. Among liver cancers, hepatocellular carcinoma (HCC) is the 62 
most common primary liver cancer. Decompensation of liver function and the 63 
development of HCC are dreaded complications of advanced liver diseases. The annual 64 
incidence of HCC in the adult Taiwanese population remains high despite the fact that 65 
here has been a more than 50% drop in HCC incidence following national hepatitis B 66 
virus (HBV) vaccination programs in Taiwan [2]. A large population with chronic HBV 67 
infection remains at risk of developing cirrhosis and HCC if left untreated [2]. Recent 68 
progress in treatments for the hepatitis C virus (HCV) has been shown to significantly 69 
alter the natural progression to HCC in countries with HCV as a major contributor to 70 
HCC [3]. However, a large population with chronic HCV infection is still at risk of 71 
developing cirrhosis and HCC if left untreated [3]. Despite the progress in imaging 72 
modalities, it is still difficult to detect the early stages of HCC [4]. Other than a liver 73 
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transplantation, it is difficult to cure patients with HCC because many of the patients 74 
have liver cirrhosis [4]. 75 
Sorafenib is the only approved multiple kinase inhibitor for the systemic 76 
chemotherapeutic reagents for compensated cirrhotic patients with unresectable or 77 
metastatic HCC, although the complete response rate to sorafenib in HCC is relatively 78 
low (0.7%-3%) [5]. Molecular targets of sorafenib are tyrosine kinases of the vascular 79 
endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor 80 
(PDGFR) [6]. Sorafenib also exerts its effects by targeting mitogen-activated protein 81 
kinase (MAPK) kinase kinase (Raf)/MAPK kinase (MEK)/MAPK [originally called 82 
extracellular signaling-related kinase (ERK)] signaling at the level of Raf kinase [6,7]. 83 
The success of anticancer treatment with sorafenib would depend on having a better 84 
understanding of its acquired resistance mechanism in HCC [7]. 85 
Stress-activated protein kinases (SAPKs)/Jun proto-oncogene (c-Jun) N-86 
terminal kinases (JNKs) are members of the MAPK family that are activated by cellular 87 
environmental stresses, inflammatory cytokines and growth factors [8, 9]. JNK1 binds 88 
to the c-Jun transactivation domain and phosphorylates c-Jun, and JNK1 activation 89 
plays a role in tumor promotion [8]. The JNK signaling pathway plays an important role 90 
in cellular apoptosis [10] and in a cisplatin (CDDP) resistance mechanism in cancer 91 
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cells [9]. A previous study [10] showed that the transcription factor c-Jun/AP-1 92 
promoted HBV-related liver tumorigenesis in mice. 93 
 In the present study, we demonstrated that c-Jun was elevated in human 94 
hepatoma cells treated with sorafenib. We report that the expression and 95 
phosphorylation of c-Jun conferred sorafenib resistance in human hepatoma cells. These 96 
mechanisms might play an important role in the chemoresistance of HCC patients 97 
treated with sorafenib.  98 
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Materials and Methods 99 
Cell culture 100 
Human hepatoma cell lines Huh7, Huh6, PLC/PRF/5, Hep3B, HepG2 and HepG2.2.15 101 
were grown in Roswell Park Memorial Institute medium (RPMI1640) (Sigma-Aldrich, 102 
St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS), 200 U/mL of 103 
penicillin, and 200 μg/mL of streptomycin at 5% CO2 and 37°C. Huh7, HepG2 and 104 
HepG2.2.15 were previously reported [11, 12]. Huh6 and PLC/PRF/5 were purchased 105 
from the National Institutes of Biomedical Innovation, Health and Nutrition JCRB Cell 106 
Bank (Ibaraki, Osaka, Japan). Hep3B cells were obtained from American Type Culture 107 
Collection (ATCC) (Manassas, VA, USA). 108 
 109 
Reagents 110 
Sorafenib and JNK inhibitor SP600125 were purchased from Cayman Chemical (Ann 111 
Arbor, MI, USA) and AdooQ BioScience (Irvine, CA, USA), respectively. 112 
 113 
RNA extraction, cDNA synthesis and human MAPK signaling 114 
targets PCR array 115 
Approximately 1.0 x 105 cells per well were plated into a 6-well plate and, 12 hours later, 116 
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were treated with or without 10 μM sorafenib (Cayman Chemical, Ann Arbor, MI, USA) 117 
[14]. Cellular RNA was extracted by an RNeasy Mini Kit (Qiagen, Hilden, Germany). 118 
cDNA was synthesized with an RT2 First Strand cDNA Kit (Qiagen) according to the 119 
manufacturer's protocol [15]. A human MAPK signaling pathway PCR array was 120 
purchased from Qiagen. A real-time PCR array based on the SYBR Green method was 121 
performed onto a 7300 Real-Time PCR system (Applied Biosystems, Foster, CA, USA). 122 
The cycling program was as follows: 95°C for 10 minutes for 1 cycle, then 40 cycles of 123 
95°C for 15 seconds and 60°C for 1 minute. The house-keeping genes beta-2-124 
microglobulin (B2M), hypoxanthine phosphoribosyltransferase 1 (HPRT1), ribosomal 125 
protein L13a (RPL13A), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 126 
actin beta (ACTB) served as internal control. Data were analyzed using the RT2 Profiler 127 
PCR Array Data Analysis software 128 
(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). 129 
 130 
Western blotting 131 
Cells were collected in 1% sodium dodecyl sulfate (SDS) buffer. After sonication, 132 
proteins were subjected to electrophoresis on a 5-20% SDS-polyacrylamide gel and 133 
transferred onto a polyvinylidene difluoride membrane (ATTO, Tokyo, Japan) followed 134 
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by overnight blocking with 5% skim milk in phosphate-buffered saline with Tween 20 135 
(Bio-Rad, Hercules, CA, USA). The membrane was probed with antibodies specific to 136 
phosphorylation of c-Jun [p-c-Jun (Ser63)], c-Jun (Cell Signaling, Boston, MA, USA), 137 
osteopontin, GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or β-tubulin 138 
(Abcam, Eugene, OR, USA). After washing the membrane, it was incubated with 139 
secondary horseradish peroxidase-conjugated antibodies for an hour. Signals were 140 
detected with enhanced chemiluminescence (GE Healthcare, Tokyo, Japan) and scanned 141 
with the image analyzer LAS-4000 (Fuji Film, Tokyo, Japan). Band intensities were 142 
determined using the ImageJ software [13]. 143 
 144 
Transfection of siRNA 145 
The siRNA against c-Jun (si-c-Jun) and control siRNA (si-C) were purchased from Santa 146 
Cruz Biotechnology [11]. Transfections were performed with 50 nM si-c-Jun, or 50 nM 147 
si-C using Effectene Transfection Reagents (Qiagen) according to the manufacturer’s 148 
protocol [15]. 149 
 150 
Overexpression of MEKK and reporter assay for AP-1 151 
activation 152 
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To overexpress c-Jun, MEKK upstream of c-Jun was overexpressed using the plasmid 153 
pMEKK (Agilent Technologies, Tokyo, Japan) [11]. The combination of c-Jun with c-Fos 154 
forms the activator protein-1 (AP-1) early response transcription factor. Cells were seeded 155 
onto a 6-well plate. After 24 hours, 0.2 μg of the reporter plasmid pAP-1-luc (PathDetect 156 
Cis-Reporting Systems; Agilent Technologies, Santa Clara, CA, USA) and 0.01 μg 157 
pMEKK were co-transfected using Effectene transfection reagents (Qiagen). After 158 
incubation for 48 hours, the cells were harvested using reporter lysis buffer (Toyo Ink, 159 
Tokyo, Japan), and the luciferase activities were determined by a Picagene system (Toyo 160 
Ink) using a luminometer (Luminescencer-JNR II AB-2300, ATTO). 161 
 162 
MTS assay 163 
To determine cell proliferation, a CellTiter 96 AQueous One Solution Cell Proliferation 164 
Assay (Promega, Madison, WI, USA) was performed. Living cells converted 5-(3-165 
carboxymethoxyphenyl)-2-(4,5-dimenthylthiazoly)-3-(4-sulfophenyl) tetrazolium, inner 166 
salt (the MTS tetrazolium compound) to formazan. The cells were grown in 96-well plates 167 
for 24 hours before the medium was replaced with 0.2 mL of fresh medium containing 168 
sorafenib. After incubating the cells for 12 hours, 20 μL of MTS solution was added to 169 
each well. Four hours later, the absorbance at 490 nm of each well was measured with the 170 
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iMark Microplate Absorbance Reader (Bio-Rad). 171 
 172 
Apoptosis assay 173 
Quantification of apoptosis was performed with the APOPercentage apoptosis assay 174 
(Biocolor, Belfast, Northern Ireland). Purple-red stained cells were identified as apoptotic 175 
cells by light microscopy. Purple-red cells/fields of 400-fold views were counted as 176 
previously described [11]. 177 
 178 
Caspase-3/-7 activity 179 
Determination of caspase-3 and -7 activity was performed with a Caspase-Glo 3/7 assay 180 
(Promega) according to the manufacturer’s instructions [11]. Luminescence was 181 
measured using Luminescencer-JNR II AB-2300 (ATTO). 182 
 183 
Statistical analysis 184 
Data are expressed as mean ± standard deviation (SD). Comparisons were analyzed using 185 
Student’s t test. Significance was defined as a P-value lower than 0.05.   186 
13 
Haga Y 
Results 187 
Human hepatoma cell lines possessed sorafenib resistance after 188 
treatment with 10 μM sorafenib for 12 hours 189 
To explore the mechanism underlying sorafenib resistance, we first examined the effects 190 
of sorafenib on cell proliferation in 6 human hepatoma cell lines: PLC/PRF/5, 191 
HepG2.2.15, Huh6, Hep3B, HepG2 and Huh7 (Fig 1). Cells were incubated with 192 
sorafenib at various concentrations for 12 hours, and cell proliferation was evaluated by 193 
an MTS Cell Proliferation assay. Although sorafenib reduced cell proliferation in a dose-194 
dependent manner, we noticed that when the cells were incubated with 10 μM sorafenib, 195 
only 8.4%, 11.6%, 25.8%, 18.2%, 7.9% and 34.5% inhibition was observed in 196 
PLC/PRF/5, HepG2.2.15, Huh6, Hep3B, HepG2 and Huh7 cells, respectively, compared 197 
to untreated controls (Fig 1). Treatment with 20 μM sorafenib for 12 hours significantly 198 
reduced cell proliferation in all cell lines except PLC/PRF/5 cells, compared to untreated 199 
controls (Fig 1). Treatment with 40 μM sorafenib for 12 hours significantly reduced cell 200 
proliferation in all cell lines compared to untreated controls (Fig 1). When cells were 201 
incubated with sorafenib at 10 μM for 24 hours, 51.6%, 36.5%, 16%, 40.2%, 10.8% and 202 
29.1% inhibition was observed in PLC/PRF/5, HepG2.2.15, Huh6, Hep3B, HepG2 and 203 
Huh7 cells, respectively, compared to untreated controls. The highest achievable clinical 204 
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blood concentration of sorafenib is 10 μM [14]. In total, 65.5% - 92.1% of human 205 
hepatoma cell lines were viable in the treatment with sorafenib at this concentration for 206 
12 hours. 207 
 208 
c-Jun was upregulated after treatment with sorafenib in 209 
human hepatoma cell lines 210 
Sorafenib is a multiple kinase inhibitor that inhibits Raf/MEK/MAPK signaling. We 211 
expected that some genes in this signal pathway might be overexpressed in sorafenib-212 
resistant cells. Next, we examined the signaling pathway related to 84 MAPK-signaling 213 
pathway-associated genes in 6 human hepatoma cell lines treated with or without 214 
sorafenib (Fig 2, Fig S1 and Tables S1-9 in File S1). Among these genes, MAP kinase 215 
interacting serine/threonine kinase 1 (MKNK1) was significantly downregulated (0.49-216 
fold, p=0.0128) in human hepatoma cells treated with 10 μM sorafenib (Fig 2A). These 217 
results also indicated that sorafenib could inhibit MAPK-signaling pathway-associated 218 
gene expression. Among those genes, we found that c-Jun was the only gene significantly 219 
upregulated (4.27-fold, p=0.0125) among a total of 6 cell lines treated with 10 μM 220 
sorafenib. 221 
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 We compared gene expression in human hepatoma cells without HBV genome 222 
integration (Huh6, HepG2 and Huh7) treated with or without 10 μM sorafenib (Fig 2B). 223 
Mitogen-activated protein kinase 10 (MAPK10), which is known as JNK3, was 224 
significantly downregulated (0.58-fold, p=0.0206) among the cells treated with 10 μM 225 
sorafenib. MKNK1 tended to be downregulated (0.56-fold, p=0.0890) in cells treated 226 
with 10 μM sorafenib.  227 
We also compared gene expression in human hepatoma cells with HBV genome 228 
integration (PLC/PRF/5, HepG2.2.15 and Hep3B) treated with or without 10 μM 229 
sorafenib (Fig 2C). c-Jun was significantly upregulated (8.58-fold, p=0.000935) and cell 230 
division cycle 42 (CDC42: GTP binding protein, 25 kDa) was significantly 231 
downregulated (0.72-fold, p=0.0389) in cells treated with 10 μM sorafenib. 232 
 233 
Phosphorylation of c-Jun increased after treatment with 234 
sorafenib in human hepatoma cell lines 235 
Compared to untreated cells, c-Jun gene expression was 17.29-, 12.94-, 8.62-, 2.82-, 1.17-, 236 
and 0.95-fold in 10 μM sorafenib-treated PLC/PRF/5, HepG2.2.15, Huh6, Hep3B, 237 
HepG2, and Huh7 cells, respectively. So we mainly used PLC/PRF/5 and HepG2.2.15 for 238 
additional analyses. We then examined the effects of sorafenib in the phosphorylation of 239 
16 
Haga Y 
c-Jun and c-Jun protein expression in PLC/PRF/5 and HepG2.2.15 cells treated with 10 240 
μM sorafenib. Treatment of PLC/PRF/5 cells with sorafenib was associated with 1.51-241 
fold and 1.59-fold increases in the phosphorylation of c-Jun and c-Jun protein expression, 242 
respectively (Fig 3A-3C), and treatment of HepG2.2.15 cells with sorafenib was 243 
associated with 1.78- and 2.05-fold increases in the phosphorylation of c-Jun and c-Jun 244 
protein expression, respectively (Fig 3D-3F). These results suggested the possibility that 245 
the expression and phosphorylation of c-Jun could be associated with sorafenib resistance. 246 
 247 
Knockdown of c-Jun enhanced sorafenib-induced apoptosis in 248 
human hepatoma cells 249 
After the efficacy of siRNAs was confirmed in hepatocytes (Fig 4A-4C), apoptotic cell 250 
death in PLC/RPF/5 cells treated with or without sorafenib following transfection with 251 
either si-c-Jun or si-C was analyzed using an APOPercentage apoptosis assay (Fig 4D). 252 
We treated the cells with 7.5 μM sorafenib for 48 hours. We used this condition because 253 
almost all cells were apoptotic when both siRNAs-transfected cells were treated with 10 254 
sorafenib for 12 hours. In sorafenib-treated PLC/RPF/5 cells transfected with si-c-Jun, 255 
apoptotic cells were significantly increased compared to sorafenib-treated PLC/RPF/5 256 
cells transfected with si-C. Compared to sorafenib-treated and si-C-transfected control 257 
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Hep3B, HepG2 and Huh7 cells, significant increases in apoptotic cells were also observed 258 
in the same cell lines when sorafenib-treated and si-c-Jun-transfected (1.81-, 1.75- and 259 
1.47-fold increase, respectively; p < 0.05 compared to si-C-transfected control cells). 260 
 261 
Overexpression of c-Jun by transfection of pMEKK into 262 
PLC/RPF/5 cells impaired sorafenib-induced apoptosis in 263 
PLC/RPF/5 cells 264 
We investigated the effects of AP-1 activation on sorafenib-induced apoptosis. As shown 265 
in Fig 5A, transfection of the pMEKK plasmids into PLC/RPF/5 cells enhanced AP-1 266 
activity in a reporter assay. In PLC/RPF/5 cells transfected with pMEKK, the expression 267 
and phosphorylation of c-Jun increased (Fig 5B-5D). Transfection with pMEKK vectors 268 
significantly reduced apoptosis in PLC/RPF/5 cells treated with sorafenib (Fig 5E). 269 
Overall, these results indicate that c-Jun is one of the factors responsible for sorafenib 270 
resistance in human hepatoma cells. 271 
 272 
JNK inhibitor SP600125 enhanced sorafenib-induced 273 
apoptosis in human hepatoma cells 274 
SP600125 prevented the activation of JNK. We next examined the effects of SP600125 275 
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on sorafenib-induced apoptosis in human hepatoma cells (Fig 6). Apoptosis was analyzed 276 
in PLC/RPF/5 cells treated with or without 10 μM sorafenib for 12 hours after treatment 277 
with or without 45 μM SP600125 for 12 hours. We observed a significantly higher 278 
proportion of apoptotic cells with the combination of sorafenib and SP600125 in the 279 
APOPercentage assay (Fig 6A). Activation of caspase-3/-7 also supported these results 280 
(Fig 6B). In HepG2.2.15 cells, the results were similar to those obtained for PLC/RPF/5 281 
cells (Fig 6C and 6D). In addition, we also observed a significantly higher proportion of 282 
apoptotic cells with the combination of sorafenib and SP600125 in HepG2 cells by 283 
APOPercentage assay (5.58-fold; p < 0.05 compared to sorafenib-treated control cells). 284 
We also examined the effects of SP600125 on the anti-cancer-drug-induced 285 
apoptosis in PLC/RPF/5 cells. The degree of apoptosis was similar in the presence of 16 286 
μM cis-diamminedichloro-platinum (CDDP) with or without 45 μM SP600125 (11.2 ± 287 
4.4% vs. 6.8 ± 0.69%, respectively). Apoptosis was also similar in the presence of 0.5 288 
μg/mL 5-fluorouracil (5FU) with or without 45 μM SP600125 (7.7 ± 0.7% vs. 6.0 ± 2.0%, 289 
respectively). However, apoptosis in the presence of 100 nM gemcitabine (GEM) with 45 290 
μM SP600125 was higher than that in the absence of GEM (2.7% ± 0.5% vs. 6.7 ± 1.6%, 291 
p = 0.040). 292 
 293 
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Sorafenib enhanced expression of osteopontin, an AP-1 target 294 
gene, in human hepatoma cell lines 295 
To investigate the mechanism further, we focused on osteopontin, an established AP-1 296 
target gene [16]. We confirmed that knockdown of c-Jun led to a decrease in the 297 
expression of osteopontin in PLC/RPF/5 cells (Fig 7A, 7B). After treatment with 298 
sorafenib in human hepatoma cell lines, we also observed that the expression of 299 
osteopontin increased (Fig 7C-7F).  300 
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Discussion 301 
In this study, we focused on the transcription factor c-Jun and demonstrated that c-Jun 302 
was involved in the resistance of sorafenib in certain human hepatoma cell lines. We 303 
showed that c-Jun and its phosphorylation determined sorafenib-induced apoptosis in 304 
human hepatoma cell lines. Inhibiting c-Jun could enhance the apoptosis of human 305 
hepatoma cells in the presence of sorafenib. We also demonstrated that osteopontin may 306 
contribute to these phenomena. Our observations indicated that c-Jun plays an important 307 
role in sorafenib resistance in HCC. 308 
The RAS-RAF-MEK-MAPK pathway is a key signal transduction pathway in 309 
cells and is constitutively active in HCCs [17]. It is also responsible for poor prognosis 310 
and drug resistance [7]. Targeting the responsible proteins, such as the hepatocyte 311 
growth factor (HGF) receptor and the phosphatidylinositol-4,5-bisphosphate 3-kinase 312 
(PI3K)/ AKT serine/threonine kinase (AKT) pathways, are also essential [7]. 313 
Drug resistance was also associated with epithelial-mesenchymal transition 314 
(EMT) in HCC [18]. In anoikis-resistant HCC cells, which are highly sorafenib-resistant 315 
and induce EMT, cellular apoptosis was associated with c-Jun [19]. OCT4, one of the 316 
pluripotency genes, regulates EMT and is associated with chemoresistance [20]. 317 
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Positive feedback regulation of OCT4 and c-Jun could expedite cancer stemness in liver 318 
cancer [21]. 319 
 Fibrosis, which is one of the features of collagen-rich microenvironments, 320 
could reduce the efficacy of sorafenib by impairing delivery of chemotherapeutics and 321 
promoting aggressive neoplastic cell behavior [22]. JNK is an important component that 322 
converts external stimuli into a wide range of cellular responses, such as fibrosis [23]. 323 
Sorafenib is a bi-aryl urea: N-(2-trifluoromethyl-4-chlorophenyl)-N´-(4-[2-324 
methylcarbamoyl pyridine-4-yl] oxyphenyl) urea [14]. Sorafenib is bound to human 325 
plasma proteins, and albuminemia influences the total clearance of sorafenib [25]. 326 
Albumin is synthesized in the liver and in cirrhotic liver, and this mostly occurs in the 327 
background in livers of HCC patients, and seems to affect the blood concentration of 328 
sorafenib. Sorafenib is metabolized by CYP3A4 and uridine diphosphate 329 
glucuronosyltransferase 1A9 (UGT1A9) in the liver [26]. Co-administration of a proton 330 
pump inhibitor led to a significant drop in sorafenib exposure [27]. Clinicians should 331 
also pay attention to these factors. 332 
 Trierweiler et al. [16] reported that c-Jun/AP-1 promoted HBV-related liver 333 
tumorigenesis in mice. Cheng et al. [28] demonstrated that sorafenib-treated patients 334 
with HBV-associated HCC had fewer survival benefits than in those with non-HBV 335 
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related HCC. Half maximal (50%) inhibitory concentration (IC50) for sorafenib was 336 
significantly higher in HBV-positive HCC cells than in those without HBV infection 337 
[29]. We also observed that c-Jun was highly upregulated in HBV-associated human 338 
hepatoma cells treated with sorafenib (Fig 2B and 2C).  339 
We also compared gene expression in the human hepatoma cell line Huh7 340 
harboring HCV subgenomic replicon [30] treated with or without 10 μM sorafenib. 341 
However, c-Jun was not significantly upregulated. The HCV-associated liver cancer cell 342 
lines do not include HCV genome integration or full-length HCV RNA [30]. Further 343 
study will be needed to investigate virally mediated oncogenesis. 344 
In HCC-patients treated with sorafenib, the expression of phosphorylated c-Jun 345 
in HCC was significantly higher in the non-responder group than in the responder group 346 
[31]. Chen et al. [32] also reported that activation of c-Jun predicted a poor response to 347 
sorafenib in HCC. Our results supported these facts. Phosphorylated-JNK was 348 
correlated with the activation of c-Jun/AP-1 proteins in HCC [33]. 349 
 CD133, identified as one of the cancer stem cell markers, contributed to the 350 
initiation and growth of HCC [31]. Phosphorylated c-Jun was also correlated with 351 
CD133 in HCC [31]. It was reported that a high percentage of cells was arrested in the 352 
G2 phase 48 hours after treatment with a JNK inhibitor [34]. Combination treatment 353 
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with SP600125 and TNF-related apoptosis-inducing ligand (TRAIL) led to apoptosis in 354 
human hepatoma cells [34]. SP600125 is known to inhibit other genes such as TNF, 355 
which is one of the nuclear factor-kappa B (NF-κB) target genes [35]. Expression of 356 
conserved helix-loop-helix ubiquitous kinase (CHUK), an inhibitor of the transcription 357 
factor NF-κB complex, was unaltered either with or without sorafenib treatment (S2 358 
file). 359 
Osteopontin is a multi-functional cytokine that is involved in cell survival, 360 
migration and chemotherapy-resistance, including sorafenib-resistance in patients with 361 
metastatic renal cell carcinoma [36, 37]. We also observed that sorafenib upregulated 362 
osteopontin expression in human hepatoma cell lines and that c-Jun played a role to 363 
some extent in this step (Fig 7). Further study of these trends will be needed. 364 
 Although there are conflicting opinions about whether sorafenib also 365 
suppresses JNK-dependent apoptosis [38, 39], c-Jun/AP-1 is one of the more attractive 366 
targets for the chemotherapy of cancers, including HCC [40]. In conclusion, c-Jun was 367 
associated with sorafenib resistance in human hepatoma cell lines. Modulation of c-Jun 368 
and phosphorylated c-Jun might be a potential tool for improving the response to 369 
sorafenib in HCC patients.  370 
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Figure legends 509 
Fig 1. Effects of sorafenib on cell proliferation in human hepatoma cell lines. (A) 510 
PLC/PRF/5, (B) HepG2.2.15, (C) Huh6, (D) Hep3B, (E) HepG2 and (F) Huh7 cells. The 511 
cells were treated with sorafenib at the indicated concentrations for 12 hours, and cell 512 
proliferation was evaluated by MTS assay (Promega). Data are presented as mean ± SD 513 
of triplicate samples. *p < 0.05 compared to the untreated control. 514 
 515 
Fig 2. Changes of MAPK-signaling pathway-associated genes in human hepatoma 516 
cell lines treated with or without sorafenib. Six human hepatoma cell lines were treated 517 
with or without 10 μM sorafenib for 12 hours. (A) Total expression of 6 human hepatoma 518 
cells (PLC/PRF/5, HepG2.2.15, Huh6, Hep3B, HepG2 and Huh7). Expression of 2 genes 519 
significantly changed after 12 hours of treatment with sorafenib: Jun proto-oncogene (c-520 
Jun) and MAP kinase interacting serine/threonine kinase 1 (MKNK1), which are shown 521 
in red. (B) Human hepatoma cells without HBV genome integration (Huh6, HepG2 and 522 
Huh7). Mitogen-activated protein kinase 10 (MAPK10) expression significantly changed 523 
after 12 hours of treatment with sorafenib. MAPK10 is shown in red, and c-Jun is shown 524 
in yellow. (C) Human hepatoma cells with HBV integration (PLC/PRF/5, HepG2.2.15 525 
and Hep3B). Expression of 2 genes significantly changed after 12 hours of treatment of 526 
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sorafenib: c-Jun and cell division cycle 42 (GTP binding protein, 25 kDa) (CDC42), 527 
which are shown in red. 528 
 529 
Fig 3. Sorafenib enhances expression and phosphorylation of c-Jun in human 530 
hepatoma cell lines. (A)-(C) Western blot analyses of phosphorylated-c-Jun (p-c-Jun), c-531 
Jun and GAPDH expression in PLC/PRF/5 cells treated with or without 10 μM sorafenib 532 
for 12 hours. (D)-(F) Western blot analyses of p-c-Jun, c-Jun and GAPDH expression in 533 
HepG2.2.15 cells treated with or without 10 μM sorafenib for 12 hours. (B, C, E, F) 534 
Densitometric analyses were performed using ImageJ software. Data are presented as 535 
mean ± SD of triplicate samples. *p < 0.05 compared to untreated control. 536 
 537 
Fig 4. Knockdown of c-Jun enhanced sorafenib-induced apoptosis in human 538 
hepatoma PLC/PRF/5 cells. (A)-(C) Validation of siRNAs si-c-Jun and si-control (si-539 
C). Lysates from transfected cells were immunoblotted with antibodies against p-c-Jun, 540 
c-Jun or GAPDH. GAPDH was used as internal control. Densitometric analyses were 541 
performed with ImageJ software. Data are presented as mean ± SD of triplicate samples. 542 
(D) Apoptosis in PLC/PRF/5 cells treated with or without 7.5 μM sorafenib for 48 hours 543 
after transfection with each siRNA. Apoptosis was determined by an APOPercentage 544 
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apoptosis assay (Biocolor). (B, D) Densitometric analyses were performed with ImageJ 545 
software. Data are presented as mean ± SD of triplicate samples. *p < 0.05 between two 546 
groups. 547 
 548 
Fig 5. Overexpression of c-Jun by transfection of pMEKK impaired sorafenib-549 
induced apoptosis in human hepatoma PLC/PRF/5 cells. (A) AP-1 activation 550 
following the transfection of pMEKK into PLC/PRF/5 cells. (B)-(D) Phosphorylated-c-551 
Jun (p-c-Jun) and expression of c-Jun protein were enhanced by transfection of pMEKK 552 
into PLC/RPF/5 cells. Densitometric analyses were performed with ImageJ software. (E) 553 
Apoptosis in PLC/PRF/5 cells treated with or without 10 μM sorafenib for 12 hours after 554 
transfection of pMEKK or control vectors. The number of apoptotic cells was determined 555 
by APOPercentage apoptosis assay (Biocolor). Data are presented as the mean ± SD of 556 
triplicate samples. *p < 0.05 between groups. 557 
 558 
Fig 6. SP600125 enhanced sorafenib-induced apoptosis in human hepatoma cell 559 
lines. (A, B) PLC/RPF/5, (C, D) HepG2.2.15. Apoptosis in cells treated with or without 560 
10 μM sorafenib for 12 hours after treatment with or without 45 μM SP600125 for 12 561 
hours. (A, C) The number of apoptotic cells was determined by APOPercentage apoptosis 562 
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assay (Biocolor). (B, D) Caspase-3/-7 activity was measured by Caspase-Glo 3/7 assay 563 
(Promega). Data are presented as mean ± SD of triplicate samples. *p < 0.05 between 564 
two groups. 565 
 566 
Fig 7. Sorafenib enhanced expression of osteopontin, an AP-1 target gene, in human 567 
hepatoma cell lines. (A, B) Knockdown of c-Jun decreased expression of osteopontin 568 
after 48 hours of transfection into PLC/PRF/5 cells with siRNA against c-Jun (si-c-Jun) 569 
or si-control (si-C). Lysates from transfected cells were immunoblotted with antibodies 570 
against osteopontin or β-tubulin. β-tubulin was used as internal control. (C, D) Western 571 
blot analyses of osteopontin and β-tubulin expression in PLC/PRF/5 cells treated with or 572 
without 10 μM sorafenib for 12 hours. (E, F) Western blot analyses of osteopontin and β-573 
tubulin expression in HepG2.2.15 cells treated with or without 10 μM sorafenib for 12 574 
hours. Densitometric analyses were performed with ImageJ software. Data are presented 575 
as mean ± SD of triplicate samples. *p < 0.05 between two groups. 576 
  577 
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Supporting Information 578 
S1 Fig. Heat map analysis for the expression of MAPK-signaling pathway-associated 579 
genes in 6 human hepatoma cells (PLC/PRF/5, HepG2.2.15, Huh6, Hep3B, HepG2 580 
and Huh7) treated with or without sorafenib. The six human hepatoma cell lines were 581 
treated with or without 10 μM sorafenib for 12 hours. Red color indicates genes expressed 582 
higher in cells treated with sorafenib than in those without sorafenib. Green color 583 
indicates genes expressed lower in cells treated with sorafenib than in those without 584 
sorafenib. Arrows indicate Jun proto-oncogene (JUN) and conserved helix-loop-helix 585 
ubiquitous kinase (CHUK). 586 
 587 
Table S1. List of analyzed genes. 588 
Table S2. Gene expression profiles in 6 human hepatoma cells treated with sorafenib. 589 
Table S3. Gene expression profiles in 6 human hepatoma cells treated without 590 
sorafenib. 591 
Table S4. List of housekeeping genes. 592 
Table S5. Overview of the PCR Array Performance and quality control. 593 
Table S6. Results of PCR arrays. 594 
Table S7. Scatter plot.  595 
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Table S8. Volcano plot.  596 
Table S9. Calculation. 597 
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